Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series
Abstract
ABSTRACT This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 10 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.